Song Yan, Yu Xiuli, Zang Zongmei, Zhao Guijuan
Department of Respiratory Medicine, Renmin Hospital of Zoucheng, Zoucheng - China.
Int J Biol Markers. 2018 Jan;33(1):3-9. doi: 10.5301/ijbm.5000307.
For both lung cancer patients and clinical physicians, tumor biomarkers for more efficient early diagnosis and prediction of prognosis are always wanted. Biomarkers in circulating serum, including microRNAs (miRNAs) and extracellular vesicles, hold the greatest possibilities to partially substitute for tissue biopsy. In this systematic review, studies on circulating or tissue miRNAs and extracellular vesicles as potential biomarkers for lung cancer patients were reviewed and are discussed. Furthermore, the target genes of the miRNAs indicated were identified through the miRTarBase, while the relevant biological processes and pathways of miRNAs in lung cancer were analyzed through MiRNA Enrichment Analysis and Annotation (MiEAA). In conclusion, circulating or tissue miRNAs and extracellular vesicles provide us with a window to explore strategies for diagnosing and assessing prognosis and treatment in lung cancer patients.
对于肺癌患者和临床医生而言，一直都需要能更有效地进行早期诊断和预测预后的肿瘤生物标志物。循环血清中的生物标志物，包括微小RNA（miRNA）和细胞外囊泡，最有可能部分替代组织活检。在本系统评价中，对有关循环或组织miRNA以及细胞外囊泡作为肺癌患者潜在生物标志物的研究进行了综述和讨论。此外，通过miRTarBase鉴定了所提及miRNA的靶基因，同时通过微小RNA富集分析与注释（MiEAA）分析了miRNA在肺癌中的相关生物学过程和途径。总之，循环或组织miRNA以及细胞外囊泡为我们探索肺癌患者的诊断、预后评估及治疗策略提供了一个窗口。
